Dr. Chen directs the Developmental Therapeutics Clinic (DTC) in the Division of Cancer Treatment and Diagnosis at the National Cancer Institute since 2014.  Within the DTC,  NCI facilitates the discovery and development of new anticancer drugs and drug targets, as well as piloting novel clinical trial designs that can be applied to the development of molecularly targeted agents on a national and international basis. She is the director the Advance Developmental Therapeutic Training Program which trains medical oncologists in early phase drug development. Fellows in the program have won major awards including one of the 2020 ASCO Young Investigator awards.  In the field of precision medicine, she is the co-primary investigator for  one of  the largest precision medicine trial, NCI-MATCH, primary investigator for the Molecular Profiling-Based Assignment of Cancer Therapy (MPACT) and  leading an arm for the new ComboMATCH.  Dr. Chen is also the  Chief Specialty Editor for the Frontiers Medicine:  Precision Medicine.  Interest in improving early phase clinical trials, Dr. Chen has led 2 revisions of the Common Toxicities Criteria for Adverse Events (CTCAE) and is a member of the Response Evaluation Criteria in Solid Tumors (RECIST) committee. Her other area of expertise includes rare tumor and sarcoma, leading as the primary investigator for several multicenter sarcoma studies testing immunotherapy and new novel agents. She has authored over 160 manuscripts and made presented by invitation to major oncology meetings internationally on early phase clinical trials, precision medicine, DNA repair and CTCAE. She has received 12 NIH/NCI Directors awards for her roles in drug development here at the NCI.